3
Announcements
Trials
Browse
Landscape
Phase
Phase 2/3
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Plasma cell
1
Other hematologic neoplasm
1
Lymphoid
1
Conditions
Neoplasms, Plasma Cell
1
Neoplasms
1
Lymphoma
1
Leukemia
1
Infections
1
Hematologic Neoplasms
1
Agammaglobulinemia
1
Interventions
Cyclophosphamide
10
Etoposide
6
Doxorubicin
6
Cytarabine
6
Prednisone
5
Vincristine
4
Trimethoprim, Sulfamethoxazole Drug Combination
4
Methotrexate
4
gamma-Globulins
3
Rituximab
3
Radiotherapy
3
Filgrastim
3
Ciprofloxacin
3
pegaspargase
2
nelarabine
2
etoposide phosphate
2
calaspargase pegol
2
Triptorelin Pamoate
2
Thioguanine
2
Prednisolone
2
Methylprednisolone
2
Mercaptopurine
2
Melphalan
2
Magnetic Resonance Spectroscopy
2
Immunoglobulins, Intravenous
2
Dexamethasone
2
Daunorubicin
2
Cyclosporine
2
Calcium Dobesilate
2
Bortezomib
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2/3
×
Lymphoma
×
Clavulanic Acid
×
Clear all
NCT05678621
2024-04-19
RATIONALISE
Monash University
Phase 2/3
Recruiting
300 enrolled